HELX ETF Profile

Family:	Franklin Templeton
Name:	Franklin Genomic Advancements ETF

Inception Date:	25-Feb-2020
Termination Date:
Investment Objective:	The Fund invests at least 80% of its net assets in equity securities of companies that are relevant to the Fund s investment theme of genomic advancements. The Fund invests predominantly in common stock. The Fund s investment theme of genomic advancements are those that the investment manager believes are substantially focused on and/or are expected to substantially benefit from extending and enhancing the quality of human and other life (e.g., animals) by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business, such as by offering new products or services that rely on genetic engineering, gene therapy, genome analysis, DNA sequencing, synthesis or instrumentation. These companies may include those that research, develop, produce, manufacture or significantly rely on or enable bionic devices, bio-inspired computing, bioinformatics, molecular medicine and diagnostics, pharmaceuticals and agricultural applications of genomics, and related equipment, techniques and processes.

Prospectus

Top 10 Holdings
NATERA INC	NTRA	5.8000%
VERTEX PHARMACEUTICALS INC	VRTX	5.7100%
ELI LILLY + CO	LLY	4.4900%
KRYSTAL BIOTECH INC	KRYS	4.4200%
SAMSUNG BIOLOGICS CO LTD	207940	4.3400%
MEDPACE HOLDINGS INC	MEDP	3.9700%
DANAHER CORP	DHR	3.9700%
THERMO FISHER SCIENTIFIC INC	TMO	3.9500%
REGENERON PHARMACEUTICALS	REGN	3.9300%
BIONTECH SE ADR	BNTX	2.5500%
	Top 10 Holdings Weight:	43.1%